Pulmonary Drug Delivery Systems Market Size & Share, by Product (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, Accessories); Application (Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4410
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Pulmonary Drug Delivery Systems Landscape

top-features-companies
    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Lupin Limited
    • Briggs Healthcare, Inc.
    • Boehringer Ingelheim International GmbH
    • Koninklijke Philips N.V.
    • Merck & Co., Inc.
    • 3M Company
    • AstraZeneca PLC
    • GSK plc
    • GF Health Products, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Novartis AG reported that a new treatment option for Japanese patients was approved by the Ministry of Health, Labour, and Welfare (MHLW). NSCLC with METex14 mutations can be treated with TabrectaTM (capmatinib, formerly INC280), an oral MET inhibitor. Tabrecta became the first-line approved treatment type for patients living with lung cancer advanced non-small cell lung cancer.

  • Lupin Limited launched Adhero, a smart inhaler tracking device designed to support the treatment of COPD patients and respiratory diseases. Adhero also provide therapy and assistance to the people living with chronic respiratory diseases. Additionally, Adhero is getting fame owing to the fact that inhalers are most convenient treatment methods for chronic respiratory diseases. 


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4410
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of chronic respiratory diseases as air pollution is increasing are the major factors driving the market growth.

The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023-2035.

Side effects related to long term use of the product are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, distribution channel, and by region.

The COPD segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying